In obesity, intestinal motility tends to be higher, meaning peristaltic activity and the speed of movement through the intestines are increased. This reflects changes in gut neural and hormonal signaling that amplify propulsion of contents along the tract. Faster transit through the small intestine can result from this heightened motility. If transit time were longer, or if there were no change, that would imply slower or unchanged movement, which doesn’t fit the pattern typically observed with obesity. While not universal for every individual, the best-supported pattern is increased intestinal motility.

Central adiposity is a key driver of metabolic risk in youth, sometimes more telling than overall weight, because fat stored around the abdomen is more closely linked to insulin resistance and cardiovascular risk. To capture this distribution, waist measurements are used. Waist circumference percentiles, which account for age and sex, provide a direct read on abdominal fat burden. Waist-to-height ratio (WHtR) offers a simple, height-adjusted index that correlates with health risk across many ages, making it a practical tool in pediatric screening. Arm circumference doesn’t specifically reflect visceral or central fat, and skinfold thickness at the triceps estimates subcutaneous fat rather than where fat is most metabolically active. Hip circumference measures gluteofemoral fat and isn’t as informative about central adiposity or metabolic risk. So, measuring waist circumference percentiles (and using waist-to-height ratio) best assesses central adiposity and associated metabolic risk in youth.

Orlistat blocks the digestion and absorption of fat by inhibiting pancreatic lipase. This not only reduces fat intake but also diminishes absorption of fat-soluble vitamins A, D, E, and K, which depend on dietary fat. Because of this, clinicians should monitor levels of these fat-soluble vitamins and consider supplementation if deficiencies arise. Water-soluble vitamins aren’t the primary concern here, and monitoring calcium or no monitoring at all would miss the key risk of fat-soluble vitamin malabsorption.

Medications for weight management are approved only when trials show meaningful, sustained weight loss with acceptable safety. Lisdexamfetamine hasn’t been approved for obesity because the weight loss it produces in studies isn’t substantial enough to meet regulatory standards, and it carries risks like potential misuse and cardiovascular effects. In contrast, orlistat, phentermine, and liraglutide have demonstrated clinically meaningful weight loss in obesity trials and have regulatory approval, though each has its own safety considerations.